Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Cash (2017 - 2025)

Historic Change in Cash for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $57.2 million.

  • Crinetics Pharmaceuticals' Change in Cash rose 27846.69% to $57.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$206.4 million, marking a year-over-year decrease of 21828.01%. This contributed to the annual value of $209.6 million for FY2024, which is 84334.05% up from last year.
  • Per Crinetics Pharmaceuticals' latest filing, its Change in Cash stood at $57.2 million for Q3 2025, which was up 27846.69% from -$40.8 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Change in Cash peaked at $341.0 million during Q1 2024, and registered a low of -$170.0 million during Q1 2025.
  • For the 5-year period, Crinetics Pharmaceuticals' Change in Cash averaged around $979684.2, with its median value being -$1.6 million (2023).
  • Data for Crinetics Pharmaceuticals' Change in Cash shows a peak YoY increase of 390219.46% (in 2024) and a maximum YoY decrease of 561371.12% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Crinetics Pharmaceuticals' Change in Cash stood at $39.2 million in 2021, then plummeted by 95.5% to $1.8 million in 2022, then plummeted by 5091.37% to -$87.9 million in 2023, then surged by 40.02% to -$52.7 million in 2024, then skyrocketed by 208.44% to $57.2 million in 2025.
  • Its last three reported values are $57.2 million in Q3 2025, -$40.8 million for Q2 2025, and -$170.0 million during Q1 2025.